Rationale and Design of a Large-Scale Trial Using Atrial Natriuretic Peptide (ANP) as an Adjunct to Percutaneous Coronary Intervention for ST-Segment Elevation Acute Myocardial Infarction-Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP (J-WIND-ANP)-

DOI Web Site PubMed 13 Citations 29 References
  • Asakura Masanori
    Research Fellow of the Japan Society for the Promotion of Science for Young Scientists
  • Jiyoong Kim
    Cardiovascular Division of Medicine, National Cardiovascular Center
  • Minamino Tetsuo
    Research Resident of Japan Foundation for Aging and Health for Medical Frontier Strategy Research by Health and Labor Sciences Research Grants
  • Shintani Yasunori
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine
  • Asanuma Hiroshi
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine
  • Kitakaze Masafumi
    Cardiovascular Division of Medicine, National Cardiovascular Center
  • the J-WIND Investigators

Bibliographic Information

Other Title
  • Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP (J-WIND-ANP)

Search this article

Description

Background The benefits of percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are limited by reperfusion injury. In animal models, atrial natriuretic peptide (ANP) reduces infarct size, so the Japan-Working groups of acute myocardial Infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP) designed a prospective, randomized, multicenter study, to evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and improves regional wall motion. Methods and Results Twenty hospitals in Japan will participate in the J-WIND-ANP study. Patients with AMI who are candidates for PCI are randomly allocated to receive either intravenous ANP or placebo administration. The primary end-points are (1) estimated infarct size (Σcreatine kinase and troponin T) and (2) left ventricular function (left ventriculograms). Single nucleotide polymorphisms (SNPs) that may be associated with the function of ANP and susceptibility of AMI will be examined. Furthermore, a data mining method will be used to design the optimal combinational therapy for post-MI patients. Conclusions J-WIND-ANP will provide important data on the effects of ANP as an adjunct to PCI for AMI and the SNPs information will open the field of tailor-made therapy. The optimal therapeutic drug combination will also be determined for post-MI patients. (Circ J 2004; 68: 95 - 100)<br>

Journal

  • Circulation Journal

    Circulation Journal 68 (2), 95-100, 2004

    The Japanese Circulation Society

Citations (13)*help

See more

References(29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top